

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000027 A2

(51) International Patent Classification: Not classified (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/22270

(22) International Filing Date: 26 June 2002 (26.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/300,933 26 June 2001 (26.06.2001) US

(71) Applicant (for all designated States except US): NORTH CAROLINA STATE UNIVERSITY [US/US]; 2401 Research Drive, Campus Box 8210, Raleigh, NC 27695-8210 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MARTIN, Linda, D. [US/US]; 8613 Cazatina Court, Apex, NC 27502 (US). ADLER, Kenneth, B. [US/US]; 5301 Wood Valley Dr., Raleigh, NC 27613 (US). LI, Yuehua [CN/US]; 2347 Champion Court, Raleigh, NC 27606 (US).

(74) Agent: ABRAMSON, Jarett, K.; Myers Bigel Sibley & Sajovec, PO Box 37428, Raleigh, NC 27627 (US).



WO 03/000027 A2

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BLOCKING PEPTIDE FOR INFLAMMATORY CELL SECRETION

(57) Abstract: The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating the release of inflammatory mediators. Additionally, the present invention discloses an intracellular signaling mechanism that regulates airway mucin secretion as well as illustrating several novel intracellular targets for pharmacological intervention in disorders involving aberrant secretion of respiratory mucins and/or secretion of inflammatory mediators from membrane-bound vesicles.